Associated Genetic Biomarkers
BRAF V600A is present in 1.69% of AACR GENIE cases, with thyroid gland papillary carcinoma, cancer of unknown primary, and lung adenocarcinoma having the greatest prevalence .
BRAF V600A is a predictive biomarker for use of dabrafenib and vemurafenib in patients.
Melanoma has the most therapies targeted against BRAF V600A or its related pathways .
BRAF V600A serves as an inclusion eligibility criterion in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains BRAF V600A as an inclusion criterion, 1 is phase 1 (1 open).
Trials with BRAF V600A in the inclusion eligibility criteria most commonly target astrocytic tumor, diffuse glioma, dysembryoplastic neuroepithelial tumor, gangliocytoma, and ganglioglioma .
E7090, dabrafenib, mirdametinib, nilotinib, and trametinib are the most frequent therapies in trials with BRAF V600A as an inclusion criteria .
Significance of BRAF V600A in Diseases
BRAF is altered in 35.7% of melanoma patients .
BRAF V600A is an inclusion criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF V600A and melanoma as inclusion criteria, 1 is phase 1 (1 open) .
Dabrafenib and vemurafenib have evidence of efficacy in patients with BRAF V600A in melanoma .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.